POGO

  • Staff List
  • Contact Us

Main menu

Skip to primary content
Skip to secondary content
  • About Us
    • Our Mission and Vision
    • Childhood Cancer Care Plan
    • POGO Land Acknowledgement
    • Diversity, Equity, Inclusion
    • Our Board
    • Our Partners
    • Our Donors
    • Privacy
    • Accessibility
    • Reports
    • Newsroom
    • Job Opportunities
    • Staff List
  • Programs & Support
    • Patient Care Programs
    • Financial Assistance
    • Survivor Care
    • Cancer Resources
    • Inspiring Stories
    • Clinical and Program Advisory Committees
  • Education
    • POGO Multidisciplinary Symposium on Childhood Cancer
    • POGO Virtual Education
    • Indigenous Resource Guide
    • All Education Events & Conferences
  • Healthcare Practice
    • COVID-19 Updates
    • Pediatric Oncology Nursing
    • Clinical Practice Guidelines
    • POGO Satellite Manual
  • Research & Data
    • 2020 POGO Surveillance Report
    • POGO Research Unit
    • POGONIS – Childhood Cancer Database
    • Data Reports
    • Data Requests
  • Get Involved
    • Pajamas and Pancakes
    • Birthday Parties for POGO
    • Events
    • Volunteer
  • Ways to Give
    • Donate
    • Gifts of Stock and Securities
    • Become a Corporate Partner
    • Gifts in Honour/Memory
    • Legacy Gifts
    • Shop Online/Earn Cash Back

Blog

POGO > Blog > Education for Health Professionals > 2018 Symposium
[sharethis]

2018 Symposium


Post navigation

← Older posts

The Gordian Knot of Precision Medicine: Ethical Dilemmas and Psychosocial Impacts

Posted on September 19, 2019 by Jamie Irvine


Presentation Description:
Targeted drug therapies show promise for treating certain types of pediatric cancers. Yet, they also come with serious ethical and psychosocial implications that can have far-reaching impacts on patients, families and health professionals. Using a case-based approach with examples from Canada, Australia and the United States, this workshop will explore ethical and psychosocial implications of tumour sequencing, somatic and germline testing, and other aspects of precision medicine, and discuss potential strategies to address and mitigate them.

Speakers:
Conrad Fernandez, MD, FRCPC
Professor and Head, Pediatric Hematology/Oncology
IWK Health Centre
Senior Scientist, Beatrice Hunter Cancer Research Institute
Dalhousie University

Dr. Conrad Fernandez is Professor and Head of the Division of Pediatric Hematology Oncology at the IWK Health Centre and Dalhousie University. He is the founding Co-Chair of the Children’s Oncology Group (COG) Return of Research Results Committee and Vice Chair of the COG Bioethics Committee. He is the lead of the Ethics Node of the Terry Fox Research Institute PROFYLE Project. He is a member of the Panel on Research Ethics, which informs the research ethics policy of Canada, called the TriCouncil Policy Statement on Ethical Conduct for Research Involving Humans. He is a Senior Scientist and a Chair of the Research Committee for the Beatrice Hunter Cancer Research Institute at Dalhousie University. He is Chair of the COG Renal Tumors Committee and a member of the COG Voting Body Steering Committee.

Dr. Fernandez’s two research passions are the development of clinical trials for children with renal tumours and exploring the many ethical challenges encountered in considering the return of summary or individual research results to participants.

Steven Joffe, MD, MPH
University of Pennsylvania Perelman School of Medicine
Emanuel and Robert Hart Professor of Medical Ethics and Health Policy

Dr. Steven Joffe is the Emanuel and Robert Hart Professor of Medical Ethics and Health Policy at the University of Pennsylvania Perelman School of Medicine. He serves as Chief of the Division of Medical Ethics and directs two post-doctoral fellowships in bioethics and in the ethical, legal and social implications of genomics. He is also Professor of Pediatrics at Children’s Hospital of Philadelphia.

Dr. Joffe attended Harvard College, received his MD from the University of California at San Francisco (UCSF), and received his MPH from UC Berkeley. He trained in pediatrics at UCSF and in hematology/oncology at the Dana-Farber Cancer Institute and Boston Children’s Hospital.

Dr. Joffe’s clinical work is in pediatric stem cell transplantation. His research addresses the ethical challenges that arise in the conduct of clinical and translational investigation. He has been principal investigator of National Institutes of Health, Patient-Centred Outcomes Research Institute (NIH, PCORI) and foundation-funded studies that examine the roles and responsibilities of principal investigators in multi-centre trials, governance in learning healthcare systems, return of genetic results to research participants, and the integration of genomic sequencing technologies into cancer care. He is a member of the U.S. FDA’s Pediatrics Ethics Subcommittee and of the National Human Genome Research Institute’s Genomics and Society Working Group.

Claire Wakefield, BPsych(hons), MPH, PhD
Director Behavioural Sciences Unit
Sydney Children’s Hospital

Professor Claire Wakefield, registered psychologist, is Director of the Behavioural Sciences Unit at Sydney Children’s Hospital, Australia. She is a chief investigator on grants worth >$26M and has published >140 peer-reviewed articles. Professor Wakefield holds a prestigious NHMRC Career Development Fellowship, and a $2.7M program grant, and is Co-Director of the SPHERE Kids to Adults (K2A): Creating Healthy Futures Clinical Academic Group. She chairs the pediatrics committee for the International Psycho-Oncology Society and founded the first international early career group for professionals working in pediatric psycho-oncology. Professor Wakefield’s team has created and implemented evidence-based resources for bereaved families, parents of children with cancer, and adolescents and young adults with cancer, including 10 clinical decision aids, many of which are now endorsed and disseminated by NSW Health. With increased use of genetic testing and personalized medicine in pediatrics, her team is assessing the psychological impact of new genetic technologies on children and families and is exploring the ethical questions arising in this novel area of medicine. Her team leads the patient-reported outcomes study in the PRISM clinical trial, one of the largest personalized medicine trials for childhood cancer patients worldwide.

Posted in 2018 Symposium, Education for Health Professionals | Tagged 2018 symposium, ethics, psychosocial

Beneath the Surface: The Psychosocial Impacts of Precision Medicine

Posted on September 19, 2019 by Jamie Irvine


VIEW THE PRESENTATION

Presentation Description:
Precision medicine represents arguably the most exciting advance in pediatric oncology in recent decades. Despite great hope for this new approach to making individualized treatment recommendations for children with cancer, there will likely be associated psychosocial challenges for all stakeholders involved, including patients, parents, clinicians and scientists. Precision medicine trials are very complex, meaning that patients’/parents’ understanding about their treatment options might be limited. Healthcare professionals might also find it difficult to manage the psychosocial impacts of precision medicine for their patients. This presentation summarises the key potential impacts of precision medicine for children with cancer, their families and the professionals who care for them. Professor Wakefield will present data from recent systematic reviews, a large-scale acceptability study, plus emerging prospective data from the first 100 families enrolled in the Australian PRISM precision medicine trial for children with high-risk cancer.

Speaker:
Claire Wakefield, BPsych(hons), MPH, PhD
Director, Behavioural Sciences Unit
Sydney Children’s Hospital

Professor Claire Wakefield, registered psychologist, is Director of the Behavioural Sciences Unit at Sydney Children’s Hospital, Australia. She is a chief investigator on grants worth >$26M and has published >140 peer-reviewed articles. Professor Wakefield holds a prestigious NHMRC Career Development Fellowship, and a $2.7M program grant, and is Co-Director of the SPHERE Kids to Adults (K2A): Creating Healthy Futures Clinical Academic Group. She chairs the pediatrics committee for the International Psycho-Oncology Society and founded the first international early career group for professionals working in pediatric psycho-oncology. Professor Wakefield’s team has created and implemented evidence-based resources for bereaved families, parents of children with cancer, and adolescents and young adults with cancer, including 10 clinical decision aids, many of which are now endorsed and disseminated by NSW Health. With increased use of genetic testing and personalized medicine in pediatrics, her team is assessing the psychological impact of new genetic technologies on children and families and is exploring the ethical questions arising in this novel area of medicine. Her team leads the patient-reported outcomes study in the PRISM clinical trial, one of the largest personalized medicine trials for childhood cancer patients worldwide.

Posted in 2018 Symposium | Tagged 2018 symposium, psychosocial

2018 POGO Symposium on Childhood Cancer

Posted on November 22, 2018 by Jamie Irvine


The 2018 POGO Multi-Disciplinary Symposium on Childhood Cancer – Precision Medicine in Pediatric Oncology – examined clinical and scientific advances in precision medicine and explored how those advances are impacting the diagnosis and treatment of cancer in children.

Over 250 delegates representing a variety of disciplines attended the conference.

VIEW THE PROGRAM

Click on the session titles below to view presentations that POGO has permission to share. 

PLENARY SESSIONS

Precision Medicine in the Pediatric Oncology Clinic: From Feasibility to Clinical Impact
Katherine Janeway, MDMD, MMSc

Precision Medicine – A Paradigm Shift?
Ian F. Tannock, CM, MD, PhD, DSc
Uri Tabori, MD

Thinking Practically: Delivery of Care Considerations for New Agents
Karen Fung, MSW, RSW
Tara McKeown, RN MN NP-Paediatrics

Ethics and Consent in the Age of Precision Medicine – Forging a Path Forward
Steven Joffe, MD, MPH

Select Poster Presentations
Alexandra Zorzi, MD, FRCPC
Andrew Shuen, PhD Candidate, MD, FRCPC
Lauren Mulrooney
, Nursing Student (3rd year)
Valli Subasri, MSc candidate (Medical Biophysics)
Nicole Espinosa, BScH Candidate (Life Sciences)
Mohammad R. Alqudimat, PhD Student (Nursing)
Marta Wilejto, Assistant Professor Paediatric Hematology/Oncology
Sarah Naraine, Fourth Year Nursing Student
Ceilidh Eaton Russell, PhD
Jill Furzer, PhD candidate (health economics)

Targeted and Traditional Agents: Can We Reduce Side Effects Using Pharmacogenomic and Endogenous Biomarkers?
Richard B. Kim, MD, FRCPC

The Future of Immunotherapy, CAR-T and Beyond
Shannon L. Maude, MD, PhD

WORKSHOPS

The Evolution of Clinical Trials in Canada
Rebecca Deyell, MD, MSc, FRCPC
Josh Silvertown, PhD, MBA, MSM
Patrick Sullivan

PROFYLE/KiCS: The ABCs of Precision Medicine in Canada
Alexandra Zorzi, MD
Anita Villani, MD, MSc, FRCPC
Andrea Cote, RN, BScN

CAR-T Cell Therapy in Ontario: Opportunities and Challenges
Joerg Krueger, MD
Stacey Marjerrison, MD, MSc, FRCPC
Colleen Callahan, RN, MSN, CRN

Posted in 2018 Symposium, Education for Health Professionals | Tagged 2018 symposium, CAR-T, Clinical Trials, consent, diagnos, ethics, genetics, pharmacology, precision therapy, psychosocial, side effects

Precision Medicine in the Pediatric Oncology Clinic: From Feasibility to Clinical Impact

Posted on November 22, 2018 by Jamie Irvine


VIEW THE PRESENTATION

Speaker:
Katherine Janeway
, MD, MSc
Associate Professor of Pediatrics
Harvard Medical School Director Clinical Genomics,Dana-Farber Cancer Institute
Senior Physician and Director Solid Tumor Service, Pediatric Oncology
Dana-Farber/Boston Children’s Cancer and Blood Disorders Center

Dr. Janeway is Associate Professor of Pediatrics at Harvard Medical School, and is the Director of Clinical Genomics and of the Pediatric Solid Tumor Program at Dana Farber Cancer Institute. Her research focus is applying cancer genomics to the pediatric oncology clinic and identifying central oncogenic mechanisms, novel drug targets and new therapeutics for sarcomas, malignancies in particular need of scientific and clinical advances. As Vice Chair of the Children’s Oncology Group Bone Tumor Committee, Dr. Janeway helps set priorities for clinical investigation and guides protocol development for collaborative trials in Ewing sarcoma and osteosarcoma. She sits on national committees charged with bringing the power of genomic characterization to patient care, e.g., she co-chairs the target and agent prioritization committee for the National Cancer Institute Pediatric MATCH study. Dr. Janeway received her MD from Harvard Medical School in 2000 and a Master of Medical Science from Harvard Medical School in 2008. She completed her residency in pediatrics at Boston Children’s Hospital where she later served as chief resident. Dr. Janeway then completed her fellowship in pediatric hematology-oncology at Dana-Farber Cancer Institute/Boston Children’s Hospital where she was also chief fellow before joining the staff in 2007.

Posted in 2018 Symposium | Tagged 2018 symposium, precision therapy

Precision Medicine – A Paradigm Shift?

Posted on November 22, 2018 by Jamie Irvine


VIEW DR. Tannock’s PRESENTATION

VIEW DR. TABORI’S PRESENTATION

Presentation Description:
“Precision medicine is a paradigm shift that will produce tremendous improvements in the outcomes of patients with cancer.” This informative and entertaining debate will delve into the virtues and vices of precision medicine and examine the question of whether it really is the ‘game-changer’ many believe it to be. What side are you on?

Speakers:
Ian F. Tannock, CM, MD, PhD, DSc
Emeritus Professor of Medicine and Medical Biophysics 
Princess Margaret Cancer Centre and University of Toronto

Dr. Tannock is Emeritus Professor of Medicine and Medical Biophysics at Princess Margaret Cancer Centre and University of Toronto. He obtained his PhD from the Institute of Cancer Research, London University, England, and his MD at University of Pennsylvania, Philadelphia, USA.

His clinical expertise is in GU (Genito Urinary) and breast cancer. His research investigated methods related to cancer clinical trials, and he chaired trials for men with metastatic prostate cancer that led to licensing of drugs that are used worldwide for this disease. Dr. Tannock is an editor of the Basic Science of Oncology textbook, now in its 5th edition that is used by trainees in all branches of oncology.

Dr. Tannock was a member of the Board of Directors of the American Society of Clinical Oncology (ASCO) from 2001-2004, and chairs the ASCO working group that organizes international clinical trials workshops. He received the alumnus award from M.D. Anderson Hospital, Houston, USA (1989), the O. Harold Warwick Prize from the National Cancer Institute of Canada (2003), an honorary degree (DSc) from London University, UK (2009), and the ESMO award (2012)—the first non-European to receive this award. He has been a board member of the European Organisation for Research and Treatment of Cancer (EORTC). Dr. Tannock was appointed to the Order of Canada in December 2013.

Uri Tabori, MD
Staff Haematologist/Oncologist, Division of Haematology/Oncology
The Hospital for Sick Children

Dr. Uri Tabori is a Staff Oncologist with the Division of Haematology/Oncology and a Senior Scientist within the SickKids Research Institute, holds the Garron Family Chair in Childhood Cancer Research, and is a Principal Investigator within the Arthur and Sonia Labatt Brain Tumor research Centre at The Hospital for Sick Children. He is also a Professor in the Department of Medical Biophysics, Institute of Medical Science and Paediatrics, University of Toronto.

He received his MD at the Hebrew University in Jerusalem and completed his specialized training in pediatrics at the Sorasky Medical Centre in the Department of Haematology/Oncology at the Chaim Sheba Medical Centre and Paediatric Neuro-Oncology at The Hospital for Sick Children.

Dr. Tabori’s clinical practice focuses on the treatment of children with cancer, with a particular focus on brain tumours and cancer predisposition. Based on his clinical background and expertise, his research focuses on translational aspects of cancer originating from patients’ need, through basic discoveries and clinical trials to changes in how society is managing specific cancers. Specifically, Dr. Tabori focuses on the development of systems for early detection, intervention and therapeutics in individuals highly predisposed to developing brain tumours. He is also studying mechanisms underlying brain tumour immortality and recurrence in the context of predisposition to cancer.

Dr. Tabori has been the recipient of numerous awards, including the Canadian Cancer Society’s Bernard and Francine Dorval Prize in 2016 and the Early Researcher Award from the Ontario Ministry of Development in Innovation in 2014.

Posted in 2018 Symposium | Tagged 2018 symposium, precision therapy

Post navigation

← Older posts

Donate

Blog

Education Portal
Survivor Conference
All Categories

Categories

Newsletter Sign-Up

Please leave this field empty

@POGO4Kids

August 10, 2022

We are thrilled to share our 2022 Impact Report —demonstrating the power donors have and how their generosity has made a significant impact on the #childhoodcancercare community. Thank you. https://www.pogo.ca/about-us/reports/

Reply on Twitter 1557462517701558274 Retweet on Twitter 1557462517701558274 2 Like on Twitter 1557462517701558274 4 Twitter 1557462517701558274

Follow @POGO4Kids

Quick Links

  • For Professionals
    • Read Cancer Care Plan
    • Review our Guidelines
    • Request Research Data
  • Families & Kids
    • Get POGO AfterCare
    • Meet with a POGO Nurse
    • Get Care Closer to Home
  • For Survivors
    • Find Local Resources
    • Set Goals for your Future
    • Educate Yourself
  • Get Involved
    • Host an Event for POGO
    • Volunteer with POGO
    • Partner with POGO
  • About Us
    • Our Mission and Vision
    • Childhood Cancer Care Plan
    • POGO Land Acknowledgement
    • Diversity, Equity, Inclusion
    • Our Board
    • Our Partners
    • Our Donors
    • Privacy
    • Accessibility
    • Reports
    • Newsroom
    • Job Opportunities
    • Staff List
  • Programs & Support
    • Patient Care Programs
    • Financial Assistance
    • Survivor Care
    • Cancer Resources
    • Inspiring Stories
    • Clinical and Program Advisory Committees
  • Education
    • POGO Multidisciplinary Symposium on Childhood Cancer
    • POGO Virtual Education
    • Indigenous Resource Guide
    • All Education Events & Conferences
  • Healthcare Practice
    • COVID-19 Updates
    • Pediatric Oncology Nursing
    • Clinical Practice Guidelines
    • POGO Satellite Manual
  • Research & Data
    • 2020 POGO Surveillance Report
    • POGO Research Unit
    • POGONIS – Childhood Cancer Database
    • Data Reports
    • Data Requests
  • Get Involved
    • Pajamas and Pancakes
    • Birthday Parties for POGO
    • Events
    • Volunteer
  • Ways to Give
    • Donate
    • Gifts of Stock and Securities
    • Become a Corporate Partner
    • Gifts in Honour/Memory
    • Legacy Gifts
    • Shop Online/Earn Cash Back

©2022 Pediatric Oncology Group of Ontario

480 University Avenue, Suite 1014 | Toronto, Ontario, M5G 1V2, Canada | Charitable Registration Number: 871067245RR0001 |
1-855-FOR POGO (367-7646) | Contact Us | Website Privacy Policy | Website Disclaimer | Satellite Manual Disclaimer |